Thursday, April 20, 2017 5:53:08 PM
The new guys is being handed a cold revenue stream, at best. I agree that revenues are everything today, tomorrow and in the future.
If by some good fortune they come in at mid-2017 guidance that will put them at roughly $682,000 in total Q4 revenues (and the company said don't look for collaboration $s). So that means, optimistically Q4 revs = Q3, which equaled Q1. Given that they indicated $500-$750K of Q4 revs will be delayed into Q1, I personally don't believe they will hit mid-guidance. I suspect their revenues will be < $500,000 in total, nearly all from service revenue. I wouldn't be surprised if <$400,000.
For the NEW GUY, that's a cold start, but there is truly nothing but UPSIDE.
I personally believe they should announce Q4 revs SOONER than later and get the BAD news out of the way. It's going to be bad, admit it, reiterate the money that was left on the table (they said $500-750K) will land in Q1, and GUIDE to NO LESS THAN 2X fiscal 2017 for fiscal 2018, as Keith and IR indicated more than once that shareholders can expect triple digit (2X) growth for years to come.
Failing to guide to at least 2X, especially if $500-750K f fiscal 2017 sales will land in Q1 fiscal 2018, will be worthy of a major backside kicking behind the barn, and associated decline in market cap.
Lots of words can be written, but in the end, it's all about revenues and more importantly rapid revenue growth. As you said, dilution is the enemy, and revenues control dilution (less capital needs to be raised and the capital that is raised will be at a higher cost per share if the company is growing). If the company is not growing - they'll still need to raise capital, but it's going to be at a lower price per share than the last round ($2.75, net $2.50). And that will be painful.
As for Mr Couch's background (patient trials)... I can see that being positive for the liver patch piece of the business... 3-4 yrs down the road. Not so sure I see the fit when it comes to tissue tox testing revenue ramp.. but I'll for now assume the board made a good decision. Mr Couch has a very steep hill to climb, and he has a 200lb backpack full of rocks on his back (large OS count, significant annual burn, company history of negative surprises, and flat QoQ rev growth for a year, assuming they hit mid-guide, but it could actually be worse).
We'll see where this goes... I won't be holding any shares at close before Q4 earnings are announced, assuming the company tells us when they're going to announce. Otherwise, I could be caught holding and I won't enjoy the impact of the news after hours or the next day, I am sure.
https://investorshub.advfn.com/uimage/uploads/2017/4/20/chprz2017-04-20_14-17-10.jpg
Recent ONVO News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/18/2024 08:05:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:05:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:01:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:01:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:01:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 08:05:26 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/26/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 08:05:07 PM
- Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis • GlobeNewswire Inc. • 07/16/2024 12:05:44 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 05/31/2024 08:05:33 PM
- Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease • GlobeNewswire Inc. • 05/21/2024 12:05:35 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/14/2024 04:45:20 PM
- Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024) • GlobeNewswire Inc. • 05/14/2024 03:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 09:00:35 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/10/2024 09:15:22 PM
- Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering • GlobeNewswire Inc. • 05/09/2024 12:00:12 AM
- Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo • GlobeNewswire Inc. • 04/15/2024 12:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/09/2024 05:15:07 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/08/2024 09:56:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/08/2024 09:05:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:05:17 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/26/2024 10:09:03 PM
- Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress • GlobeNewswire Inc. • 01/25/2024 01:05:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM